IN8bio Stock Is Soaring Today: What's Behind The Move Higher?


IN8bio Inc INAB shares are ripping higher Tuesday after a Form 4 filing with the SEC showed that Cavu Advisors has been buying shares of the clinical-stage biotech company. Positive analyst coverage from HC Wainwright & Co may also be adding to the move higher.

According to a recent regulatory filing, Cavu Advisors bought 51,214 shares of IN8bio over the last week at an average price of $2.02 per share.

HC Wainwright & Co. analyst Swayampakula Ramakanth initiated coverage on IN8bio with a Buy rating Tuesday and announced a price target of $14.

IN8bio focuses on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.

See Also: Why Azure Power Global Stock Is Getting Obliterated Again Today

INAB Price Action: INAB has a 52-week high of $4.97 and a 52-week low of $1.75.

The stock was up 35.9% at $2.69 at press time, according to Benzinga Pro.

Photo: Konstantin Kolosov from Pixabay.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: BiotechPenny StocksPrice TargetAnalyst RatingsMoversTrading IdeasGeneralwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!